Literature DB >> 9797827

Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys.

M Arévalo-Herrera1, M A Roggero, J M Gonzalez, J Vergara, G Corradin, J A López, S Herrera.   

Abstract

Plasma samples of individuals from two malaria-endemic villages on the Colombian Pacific coast and synthetic peptides representing different fragments of the central and flanking regions of the Plasmodium vivax circumsporozoite protein (CSP) were used to perform a fine mapping of the B-cell epitopes on the whole CSP. In addition, the immunogenicity of long polypeptides corresponding to the amino (N) and carboxyl (C) regions was evaluated in Aotus monkeys. The epitopes recognized after natural infection of humans and after immunization of Aotus with these synthetic peptides were compared. Human samples more frequently contained specific antibodies to the central region. The type-I repeat region of the CSP was predominantly recognized by the human sera (by 68% of those from the village of Zacarías and 75% of those from Bajo Calima), a significantly smaller population reacting with the type-II repeat (20% and 11%, respectively). Most of the sera reacting with the type-I repeat recognized the minimal epitope AGDR. Although the N- and C-terminal polypeptides were both highly immunogenic in Aotus and induced long-lasting antibodies, titres of antibodies to the C-terminal polypeptide were higher than those of antibodies to the N-terminal. Competitive inhibition assays performed using human and monkey plasma allowed the identification of dominant B-cell epitopes on sequence 71-90 (p8) from the amino region and sequence 332-361 (p24/p25) from the carboxyl region. The high prevalence of naturally induced antibodies to the three epitopes, the possible functional role of the corresponding sequences, and the high immunogenicity of these epitopes in Aotus could be of great importance in the development of a malaria vaccine based on P. vivax CSP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9797827

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  17 in total

Review 1.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

3.  Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

Authors:  Sócrates Herrera; Olga Lucía Fernández; Omaira Vera; William Cárdenas; Oscar Ramírez; Ricardo Palacios; Mario Chen-Mok; Giampietro Corradin; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  Antigenic diversity of the Plasmodium vivax circumsporozoite protein in parasite isolates of Western Colombia.

Authors:  Miguel Ángel Hernández-Martínez; Ananías A Escalante; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

5.  Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.

Authors:  Myriam Arévalo-Herrera; Omaira Vera; Angélica Castellanos; Nora Céspedes; Liliana Soto; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

6.  Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites.

Authors:  Alejandro Jordán-Villegas; Anilza Bonelo Perdomo; Judith E Epstein; Jesús López; Alejandro Castellanos; María R Manzano; Miguel A Hernández; Liliana Soto; Fabián Méndez; Thomas L Richie; Stephen L Hoffman; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

7.  Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera.

Authors:  Monica Cabrera-Mora; Jairo Andres Fonseca; Balwan Singh; Joseli Oliveira-Ferreira; Josué da Costa Lima-Junior; J Mauricio Calvo-Calle; Alberto Moreno
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

8.  A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.

Authors:  Anjali Yadava; Jetsumon Sattabongkot; Michael A Washington; Lisa A Ware; Victoria Majam; Hong Zheng; Sanjai Kumar; Christian F Ockenhouse
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

9.  Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study.

Authors:  Peter Van den Eede; Veronica E Soto-Calle; Christopher Delgado; Dionicia Gamboa; Tanilu Grande; Hugo Rodriguez; Alejandro Llanos-Cuentas; Jozef Anné; Umberto D'Alessandro; Annette Erhart
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

10.  Immunoreactivity of Sera From Low to Moderate Malaria-Endemic Areas Against Plasmodium vivax rPvs48/45 Proteins Produced in Escherichia coli and Chinese Hamster Ovary Systems.

Authors:  Myriam Arévalo-Herrera; Kazutoyo Miura; Nora Cespedes; Carlos Echeverry; Eduardo Solano; Angélica Castellanos; Juan Sebastián Ramirez; Adolfo Miranda; Andrey V Kajava; Carole Long; Giampietro Corradin; Sócrates Herrera
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.